Barclays Maintains “Buy” Rating on Viatris, Sets $22 Price Target

AI-generated context summary requested by a Free News Reader user. Sourced via Gemini from publicly available information — no paywalled content was accessed.

You hit a paywall. Here’s the context on this topic based on publicly available information. We did not access any paywalled content. View original article.

Barclays Maintains "Buy" Rating on Viatris, Sets $22 Price Target

Full Summary — powered by AI

Barclays analyst Glen Santangelo has reaffirmed a “Buy” rating for Viatris (VTRS), a global healthcare company, and maintained a price target of $22.00 as of August 18, 2026. This rating aligns with a generally optimistic, though mixed, sentiment among analysts covering Viatris.

Viatris recently reported strong financial results for the second quarter of 2026 on August 6, 2026, exceeding analyst expectations for both revenue and adjusted earnings per share. The company’s total revenues reached $3.8 billion, a 5% year-over-year increase, and adjusted earnings per share were $0.69, an 11% increase. Following these results, Viatris raised its full-year 2026 financial guidance across all key metrics. The updated guidance projects total revenues between $14.55 billion and $14.95 billion, and adjusted EBITDA between $4.3 billion and $4.5 billion.

Despite the positive earnings report and raised guidance, Viatris’s stock experienced a slight decline after the Q2 announcement, reflecting some investor concerns about potential challenges in the second half of 2026, including supply disruptions, competitive pressures, and policy changes in China. However, the company’s year-to-date stock performance has shown a significant increase of over 30%.

Analyst consensus for Viatris is currently a “Moderate Buy” based on ratings from seven Wall Street analysts in the last 12 months, with four issuing “Buy” ratings and three issuing “Hold” ratings. The average 12-month price target for Viatris is $17.50, with a high of $22.00 and a low of $12.00. Other firms, such as UBS, also maintained a “Buy” rating and raised their price target to $20 in March 2026, citing the company’s achievement of cost-saving targets. BofA Securities, however, adjusted its price target to $12 while maintaining an “Underperform” rating in March 2026.

Generated by Free News Reader. This summary provides topic context based on publicly available information. We encourage supporting quality journalism by subscribing to the original publisher.